Holen Sie sich die Stockscreener-App
8.07
0.12%
-0.010
Schlusskurs vom Vortag:
$8.08
Offen:
$8.08
24-Stunden-Volumen:
3.94M
Relative Volume:
2.84
Marktkapitalisierung:
$384.83M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-82.60M
KGV:
-3.9175
EPS:
-2.06
Netto-Cashflow:
$-48.61M
1W Leistung:
+0.25%
1M Leistung:
+1.89%
6M Leistung:
+318.13%
1J Leistung:
+114.06%
1-Tages-Spanne:
$8.07
$8.09
1-Wochen-Bereich:
$8.03
$8.10
52-Wochen-Spanne:
$1.312
$8.10
Vigil Neuroscience Inc Stock (VIGL) Company Profile
Firmenname
Vigil Neuroscience Inc
Sektor
Branche
Telefon
857-254-4445
Adresse
100 FORGE ROAD, WATERTOWN
Vergleichen Sie VIGL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VIGL
Vigil Neuroscience Inc
|
8.07 | 375.71M | 0 | -82.60M | -48.61M | -2.06 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.81 | 120.40B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.52 | 61.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.53 | 41.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
564.59 | 34.29B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.55 | 27.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Vigil Neuroscience Inc Stock (VIGL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-28 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-04 | Eingeleitet | William Blair | Outperform |
| 2023-12-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-10-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-03-31 | Eingeleitet | Mizuho | Buy |
| 2022-09-16 | Eingeleitet | Wedbush | Outperform |
| 2022-08-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-02-01 | Eingeleitet | Guggenheim | Buy |
| 2022-02-01 | Eingeleitet | Jefferies | Buy |
| 2022-02-01 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-02-01 | Eingeleitet | Stifel | Buy |
Alle ansehen
Vigil Neuroscience Inc Aktie (VIGL) Neueste Nachrichten
What drives Vigil Neuroscience Inc. stock priceSuperior portfolio returns - Jammu Links News
Vigil Neuroscience Inc. Stock Analysis and ForecastFree Popular Stock Recommendations - Jammu Links News
What analysts say about Vigil Neuroscience Inc. stockUnprecedented profit potential - Jammu Links News
Vigil Neuroscience Awaits HSR Expiration for Sanofi Merger - TipRanks
Vigil Neuroscience merger with Sanofi clears U.S. antitrust waiting period By Investing.com - Investing.com South Africa
Vigil Neuroscience merger with Sanofi clears U.S. antitrust waiting period - Investing.com India
How Vigil Neuroscience Inc. stock performs during market volatilityIntraday Trade Ideas - Newser
Why Vigil Neuroscience Inc. stock attracts strong analyst attention10x Potential Stocks - Newser
What makes Vigil Neuroscience Inc. stock price move sharplyFree VIP Investment Strategies - Newser
Brokerages Set Vigil Neuroscience, Inc. (NASDAQ:VIGL) PT at $10.80 - Defense World
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SAGE, CHTR, VIGL on Behalf of Shareholders - MarketScreener
VIGIL NEUROSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Vigil Neuroscience, Inc.VIGL - The Globe and Mail
TREM2 agonists reported in Vigil Neuroscience patents - BioWorld MedTech
Vigil Neuroscience (NASDAQ:VIGL) Stock Price Up 0.4% – Here’s What Happened - Defense World
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger: TASK, VIGL, STRM, and CHTR - The Malaysian Reserve
Vigil Neuroscience Announces Special Meeting for Sanofi Merger Vote - TipRanks
VIGL to Be Acquired by Sanofi for $8 Cash + $2 CVR; Vote Aug 4 2025 | VIGL SEC FilingForm DEFM14A - Stock Titan
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Crown Electrokinetics Corp. (OTCCRKN), Elevation Oncology, Inc. (NasdaqELEV), Sitio Royalties Corp. (NYSESTR), Vigil Neuroscience, Inc. (NasdaqV - TradingView
Two Sigma Investments LP Acquires 41,836 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL) - Defense World
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HURA and VIGL on Behalf of Shareholders - MarketScreener
Wall Street Analysts Think Vigil Neuroscience (VIGL) Could Surge 26.9%: Read This Before Placing a Bet - MSN
Millennium Management LLC Boosts Holdings in Vigil Neuroscience, Inc. (NASDAQ:VIGL) - Defense World
Vigil Neuroscience: ALSP Data Doesn't Deliver, But Sanofi Purchase Remains Intact (VIGL) - Seeking Alpha
Vigil Neuroscience fails in mid-stage study for lead asset - MSN
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LSEA, FARO, TASK, VIGL on Behalf of Shareholders - marketscreener.com
Vigil Neuroscience halts Phase 2 trial for ALSP treatment By Investing.com - Investing.com South Africa
Vigil’s Iluzanebart Disappoints In Rare Neurodegenerative Disease - insights.citeline.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Flowserve Corporation (NYSE – FLS), Streamline Health Solutions, Inc. (Nasdaq – STRM), Sitio Royalties Corp. (NYSE – STR), Vigil Neuroscience, Inc. (Nasda - Morningstar
Hold Rating on Vigil Neuroscience Inc Amidst Acquisition and Trial Outcomes - TipRanks
VIGIL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Vigil Neuroscience, Inc. (NASDAQ: VIGL) Proposed Shareholder Buyout and Encourages Investors to Contact the Firm - GuruFocus
Vigil Neuroscience (VIGL) Trial Results Impact Future Plans - GuruFocus
Vigil Neuroscience halts Phase 2 trial for ALSP treatment - Investing.com Australia
Vigil Neuroscience stock slips on trial setback (VIGL:NASDAQ) - Seeking Alpha
Vigil Neuroscience (VIGL) Updates on Iluzanebart in Phase 2 Trial | VIGL Stock News - GuruFocus
Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP - marketscreener.com
Clinical Setback: Vigil Neuroscience Halts Phase 2 ALSP Trial After Iluzanebart Shows No Efficacy - Stock Titan
Northern Trust Corp Has $110,000 Stock Position in Vigil Neuroscience, Inc. (NASDAQ:VIGL) - Defense World
Vigil Neuroscience (VIGL) Updates on Iluzanebart in Phase 2 Tria - GuruFocus
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger – PRA, AXL, SWTX and VIGL - GlobeNewswire Inc.
Should You Buy Vigil Neuroscience, Inc. (VIGL) After Golden Cross? - sharewise
$HAREHOLDER NOTICE: The M&A Class Action Firm Continues To Investigate The MergerPRA, AXL, SWTX and VIGL - The Malaysian Reserve
HC Wainwright Has Bearish Estimate for VIGL FY2026 Earnings - Defense World
Sanofi to acquire Vigil Neuroscience in $470-M deal - MSN
Sanofi’s Acquisition Of Vigil Neuroscience - Global Legal Chronicle
Vigil Neuroscience (NASDAQ:VIGL) Downgraded by Stifel Nicolaus to Hold - Defense World
Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business Update - The Globe and Mail
Finanzdaten der Vigil Neuroscience Inc-Aktie (VIGL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.59%
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):